The EASE Study
Summary
This study is exploring the option of myeloma patients injecting themselves with bortezomib, a type of chemotherapy, at home instead of having to come to the cancer centre.
Eligibility
Eligible gender: Male, Female
Eligible ages: 18 to 100
Inclusion criteria:
1. 18 years old or older and diagnosed with myeloma.
2. Your oncologist feels you are healthy enough to be on the study.
3. You or your caregiver are willing and capable to inject the chemotherapy yourself with proper teaching.
4. You've previously received more than 4 injections of bortezomib (chemotherapy) in the hospital.
Exclusion criteria:
1. Currently participating in a clinical trial that includes the use of bortezomib (chemotherapy).
2. Your oncologist feels you are unlikely to follow the instructions of the study.
3. You have a history of allergic reaction to bortezomib.
4. You have a history of bleeding associated with using bortezomib.
5. You have a history of serious side effects assoicated with the use of bortezomib.
6. Your life expectancy is anticipated to be less than 6 months.
7. You live too far away from the cancer centre.
Participate
Additional information
Contact information
Ask your medical oncologist if you feel you are eligible for this study.
Principal investigator:
Jason Tay
Clinical trial:
Yes
REB-ID:
HREBA.CC-20-0048